



Medicines & Healthcare products  
Regulatory Agency

MHRA Central Freedom of  
Information Team  
10 South Colonnade  
Canary Wharf  
London  
E14 4PU

[foi.request@mhra.gov.uk](mailto:foi.request@mhra.gov.uk).

[MHRA Website](#)

Our Ref: **FOI2026/00347**

30 March 2026

Dear [REDACTED]

Thank you for your Freedom of Information (Fol) request received on 26 March. You wrote:

*Medicine used for cancer treatments (pills, liquids medicines etc), with a breakdown of this, that have been seized.*

*These are the brand/drugs names for clarification:*

- Iclusig (brand) ponatinib (drug)  IMFINZI
- Casodex (brand) bicalutamide (drug)
- Adcetris (brand) brentuximab vedotin (drug)

**MHRA Response**

We confirm that we hold the information you have requested.

Figures given in the tables are for individual doses of medicine seized.

Product	2023	2024	2025
Iclusig/ponatinib/ IMFINZI	0	0	0
Casodex/bicalutamide	0	<b>400</b> tablets. Consignment from India. Product unauthorised for use in UK as it held no marketing authorisation. Importer held no manufacturer's licence - breach of Reg 17(1)(c) and Reg 34(1) Human Medicines Regulations 2012.	0
Adcetris/brentuximab/vedotin	0	0	0

<b>Product</b>	<b>2023</b>	<b>2024</b>	<b>2025</b>
Bicalutamide	0	400	0
Exemestane	360	1230	90
Imatinib	0	0	1000
Letrozole	3650	8190	5268
Raloxifene	3560	1900	2000
Tamoxifen	21560	40150	1180
<b>Total</b>	<b>29130</b>	<b>51870</b>	<b>9538</b>

We have also identified the above seizures of medicines that may be used in the treatment of cancers. These seizures were all made at the UK border because the importer held no manufacturer's licence and the volumes involved were not compatible with the 'personal use exemption' set out at Reg 17(6) of the Human Medicines Regulations 2012.

If you have any queries about this letter, please contact us quoting the reference number above.

Yours sincerely,

MHRA Central Freedom of Information Team  
Medicines & Healthcare products Regulatory Agency

---

### **Your right to complain under the Freedom of Information Act**

If you are not happy with this response you may request an internal review by e-mailing [foi.request@mhra.gov.uk](mailto:foi.request@mhra.gov.uk) or by writing to: MHRA Central Freedom of Information Team, 10 South, Colonnade, Canary Wharf, London, E14 4PU

Any request for an internal review must be received by us within 40 working days of the date of this letter. Please note we are not obliged to provide a review if it is requested after more than 40 working days.

If you are not content with the outcome of the internal review, you may apply directly to the Information Commissioner's Office for a decision. Generally, the Commissioner cannot make a decision unless you have exhausted our own complaints procedure. The Information Commissioner can be contacted at: The Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF.

Website: [ICO FOI and EIR complaints](#) or telephone 0303 123 1113.

### **Re-use of our information**

The MHRA information supplied in response to your request is subject to Crown copyright. Information created by the MHRA which is disclosed under the Freedom of Information Act is made available for re-use under the Open Government Licence (OGL) v3.0, except where this is otherwise stated. There are some restrictions on re-use under the OGL and these can be viewed here:

<https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/>